- Home
- AUUD vs MBIO Comparison
AUUD vs MBIO Comparison
Compare AUUD & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUUD | MBIO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUUD | MBIO |
|---|---|---|
| Price | $1.00 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 75.2K | ★ 102.8K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $0.89 |
| 52 Week High | $14.60 | $21.95 |
Technical Indicators
Market Signals| Indicator | AUUD | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 37.70 |
| Support Level | $1.10 | $1.06 |
| Resistance Level | $1.25 | $1.31 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 21.78 | 8.11 |
Price Performance
Historical ComparisonAbout AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.